The "Chicken-and-Egg" Validation Success
Historically, the adoption of digital biomarkers was slowed by a "chicken-and-egg" problem: they needed to be validated to be used, but needed use to be validated. 2026 has officially broken this cycle.
Major pharma players (such as Roche and Takeda) have moved digital biomarkers from small-scale pilots to the "fabric of drug development." In 2026, the use of Real-World Data (RWD) from connected health devices—like Oura rings and continuous glucose monitors—is standard for planning trials and supporting regulatory filings. This has resulted in a 25% increase in patient adherence during clinical trials due to the less invasive nature of digital monitoring.
18 Ansichten